The Annals Evolution of Clinical Pharmacy | Now Available
home help contact us subscription past issues search current issue
QUICK SEARCH:   [advanced]


     

The Annals of Pharmacotherapy: Vol. 37, No. 9, pp. 1325-1328. DOI 10.1345/aph.1C412
© 2003 Harvey Whitney Books Company.
This Article
Right arrow Abstract Freely available
Right arrow Résumé Freely available
Right arrow Full Text
Right arrow PDF
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fulco, P. P.
Right arrow Articles by Kirian, M. A
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fulco, P. P.
Right arrow Articles by Kirian, M. A

DRUG INFORMATION ROUNDS

OBJETIVO: Evaluar la interacción farmacocinética entre tenofovir y didanosina cuando se usa de forma combinada como un régimen de terapia antiretroviral altamente activo (HAART).

FUENTES DE INFORMACIÓN: Se realizo una búsqueda de la literatura a través de MEDLINE entre 1966 a enero 2003 usando términos tales como tenofovir y didanosina. También se repasó extractos y carteles relevantes que se presentaron en conferencias recientes tales como las de la Sociedad Internacional del SIDA, la Conferencia Intercientífica Sobre Agentes Antimicrobianos y Quimioterapia (ICAAC), y la Sociedad Americana de Enfermedades Infecciosas (IDSA).

SÍNTESIS DE INFORMACIÓN: Tenofovir está aprobado para uso en combinación con otros agentes antiretrovirales en el tratamiento de la infección del VIH. La interacción entre tenofovir y didanosina fue evaluada para determinar la seguridad de esta terapia combinada.

CONCLUSIONES: Cuando se usa concurrentemente, tenofovir aumenta la concentración plasmática máxima y el área bajo la curva de concentración contra tiempo de didanosina. Se necesita datos adicionales en pacientes infectados con el VIH para determinar la toxicidad a largo plazo de esta terapia combinada. Se debe de considerar una reducción en la dosis de didanosina cuando se usan estos agentes en combinación.




This article has been cited by other articles:


Home page
 Antimicrob. Agents Chemother.Home page
A. Pruvost, E. Negredo, F. Theodoro, J. Puig, M. Levi, R. Ayen, J. Grassi, and B. Clotet
Pilot Pharmacokinetic Study of Human Immunodeficiency Virus-Infected Patients Receiving Tenofovir Disoproxil Fumarate (TDF): Investigation of Systemic and Intracellular Interactions between TDF and Abacavir, Lamivudine, or Lopinavir-Ritonavir
Antimicrob. Agents Chemother., May 1, 2009; 53(5): 1937 - 1943.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
F. Vidal, J. C. Domingo, J. Guallar, M. Saumoy, B. Cordobilla, R. Sanchez de la Rosa, M. Giralt, M. L. Alvarez, M. Lopez-Dupla, F. Torres, et al.
In Vitro Cytotoxicity and Mitochondrial Toxicity of Tenofovir Alone and in Combination with Other Antiretrovirals in Human Renal Proximal Tubule Cells
Antimicrob. Agents Chemother., November 1, 2006; 50(11): 3824 - 3832.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
P. Barreiro and V. Soriano
Suboptimal CD4 gains in HIV-infected patients receiving didanosine plus tenofovir
J. Antimicrob. Chemother., May 1, 2006; 57(5): 806 - 809.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
A. Pruvost, E. Negredo, H. Benech, F. Theodoro, J. Puig, E. Grau, E. Garcia, J. Molto, J. Grassi, and B. Clotet
Measurement of Intracellular Didanosine and Tenofovir Phosphorylated Metabolites and Possible Interaction of the Two Drugs in Human Immunodeficiency Virus-Infected Patients
Antimicrob. Agents Chemother., May 1, 2005; 49(5): 1907 - 1914.
[Abstract] [Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
M. A Kirian, R. T Higginson, and P. P. Fulco
Acute Onset of Pancreatitis with Concomitant Use of Tenofovir and Didanosine
Ann. Pharmacother., October 1, 2004; 38(10): 1660 - 1663.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
A. S. Ray, L. Olson, and A. Fridland
Role of Purine Nucleoside Phosphorylase in Interactions between 2',3'-Dideoxyinosine and Allopurinol, Ganciclovir, or Tenofovir
Antimicrob. Agents Chemother., April 1, 2004; 48(4): 1089 - 1095.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Résumé Freely available
Right arrow Full Text
Right arrow PDF
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fulco, P. P.
Right arrow Articles by Kirian, M. A
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fulco, P. P.
Right arrow Articles by Kirian, M. A

homecopy help contact us subscription past issues search current issue
Copyright © 2003 by Harvey Whitney Books Company.